HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi’s Nasacort Hay Fever Spray Latest In Post-Brexit UK Switch Boom

Executive Summary

Sanofi's Nasacort Allergy Relief hay fever spray is the latest in a flood of reclassifications in the UK since the beginning of the year when the country left the European Union.

You may also be interested in...



Reckitt Seeks UK General Sale Status For Nuromol Paracetamol + Ibuprofen Combo

Reckitt's application for a P-to-GSL switch of its Nuromol paracetamol and ibuprofen combination painkiller in the UK is out for consultation until 3 June. 

Cipla Switches Fexofenadine For Hives From Rx-To-OTC Status In The UK

UK hives sufferers can now buy a specific OTC medicine for their condition thanks to a successful Rx-to-OTC switch from Cipla. 

Oral Contraceptive Rx-to-OTC Switch On The Cusp In UK

The MHRA is consulting on two Rx-to-OTC switch applications for progestogen-only contraceptive pills containing desogestrel, one from HRA Pharma and one from Maxwellia. The move has been welcomed by UK consumer healthcare industry association, the PAGB, as well as the British Pregnancy Advisory Service. 

Related Content

Topics

UsernamePublicRestriction

Register

RS151418

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel